ClinicalTrials.gov
ClinicalTrials.gov Menu

Cyclophosphamide, Lenalidomide and Dexamethasone (CRD) Versus Melphalan (200 mg/m2) Followed By Autologous Stem Cell Transplant (ASCT) In Newly Diagnosed Multiple Myeloma Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01091831
Recruitment Status : Active, not recruiting
First Posted : March 24, 2010
Last Update Posted : September 6, 2017
Sponsor:
Information provided by (Responsible Party):
Fondazione Neoplasie Sangue Onlus